Fractionated microneedle radiofrequency versus botuinum toxin A in primary axillary hyperhidrosis

Efficacy and safety of fractionated microneedle radiofrequency versus botuinum toxin A in primary axillary hyperhidrosis: A randomized controlled clinical trial.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR201808213089174

Enrollment

Registered

2018-08-02

Start date

2018-08-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

fractionated microneedle radiofrequency

Botulinum toxin A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients older than 18 years. 2. Patients with bilateral PAH grade 3 and 4 hyoerhidrosis disease severity score (HDSS)

Exclusion criteria

Exclusion criteria: 1. History of surgery for PAH. 2. History of botulinum toxin therapy within the previous 6 months. 3. History of pacemaker implantation or any other electronic implants. 4. Active infection in the treatment area. 5. Tendency for keloid formation. 6. Pregnancy or breastfeeding. 7. Neuromuscular disease e.g. myasthenia gravis. 8. Known hypersensitivity from Botulinum toxin. 9. Autoimmune disease.

Design outcomes

Primary

Measure	Time frame
Comparative clinical effectiveness at 1, 2, 3 and 6 months, in the form of reduction of sweating in the treated site	—

Secondary

Measure	Time frame
1. Comparative safety of both interventions during the procedure, short-term (0-6 months) and long-term (6-12 months). 2. Long-term comparative clinical effectiveness (6-12 months)	—

Countries

Egypt

Contacts

Public ContactReem Osama

Demonstartor of Dermatology cairo university

reemosama1989@gmail.com00201003577387

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026